INNOVACAP1,165.00

Innova Captab Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersMOREPENLABIOLCPFDCSENORESSANOFIORCHPHARMAGUJTHEMRPGLIFEMcap ₹6,667 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,081.31,243.71,630.01,749.3
Other Income12.512.07.49.4
Total Income1,093.81,255.71,637.41,758.7
Expenses
+ Cost of Materials Consumed696.1799.81,005.51,084.0
+ Purchases of Stock-in-Trade35.539.258.365.7
+ Changes in Inventories-3.3-24.9-11.0-13.7
+ Employee Benefit Expense90.7116.8167.2172.9
+ Finance Costs21.52.416.918.5
+ Depreciation & Amortisation16.024.845.245.8
+ Other Expenses107.8126.6167.1181.0
Total Expenses964.31,084.71,449.21,554.2
EBITDA154.5186.2242.9259.5
EBIT138.5161.4197.7213.6
Profit
PBT before Exceptional Items129.5171.0188.3204.6
Pretax Income129.5171.0188.3204.6
+ Current Tax29.326.825.630.3
+ Deferred Tax5.916.021.820.2
Tax Expense35.242.847.350.5
Net Income94.3128.3140.9154.0
+ Net Income — Continuing Ops94.3128.3140.9154.0
+ Other Comprehensive Income1.90.30.40.6
Total Comprehensive Income96.2128.5141.3154.6
Per Share
Basic EPS18.6622.4124.6326.91
Diluted EPS18.6622.4124.6326.91
Other Comprehensive Income — detail
+ Other Comprehensive Income0.30.40.6
+ Items NOT to be Reclassified to P&L0.40.40.6
+ Tax on Items NOT to be Reclassified0.10.00.0
+ Tax on Items NOT to be Reclassified — alt tag-1.9
Per Share — as-filed variants
Basic EPS — Continuing Operations18.6622.4124.6326.91
Diluted EPS — Continuing Operations18.6622.4124.6326.91
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit353.0429.6577.2613.4
Gross Margin %32.6434.5435.4135.06
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)129.5171.0188.3204.6
Net Income Adj (tax-effected)94.3128.3140.9154.0
EPS Adj18.6622.4124.6326.91
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital57.257.257.257.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.